Die kostenlosen ARIVA.DE Börsen-Dienste:
Bleiben Sie immer informiert und melden Sie sich jetzt für die Newsletter von ARIVA.DE an!
Jetzt kostenlos abonnieren

Trader 2021/12: iTechDachs

Cashbestand:
33,74 €
Platz:
Gesamtwert mit Cash:
99.352,88 € (15.01.22 06:17)
Börsenspiel beendet. Diese Werte werden nicht mehr aktualisiert.
Kurse zum Spielende    

News

Zeit
Titel
Wertpapier
 
16:40 TME Pharma Announces a Financing Guarantee Agreement and the Launch of Capital Increase of Minimum 2.2 Million Euros
TME Pharma AG
15:35 TME Pharma Announces Publication in Nature Communications of Biomarker Data From NOX-A12 Gloria Phase 1/2 Trial in Glioblastoma
TME Pharma AG
08:00 Actinium Presents First Ever Data Demonstrating Actimab-A in Combination with Leading Menin Inhibitors Leads to Anti-Tumor Control and Potent Leukemic Cell Killing in Preclinical Acute Myeloid Leukemia Models at the 2024 EHA Congress
Actinium Pharmaceuticals
Fr Actinium Highlights Oral Presentation at EHA 2024 Annual Congress Featuring Improved Outcomes in TP53 Positive Patients Receiving Iomab-B in the Phase 3 SIERRA Trial
Actinium Pharmaceuticals
Di Actinium Announces Results of Actimab-A + CLAG-M Combination Trial Highlighted in Oral Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting
Actinium Pharmaceuticals
10.06.24 Actinium Highlights Mutation Data from the Phase 3 SIERRA Trial of Iomab-B and Novel Linker Technology to Support Solid Tumor Antibody Radiation Conjugate Development at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting
Actinium Pharmaceuticals
05.06.24 Epigenomics AG: BaFin setzt Geldbuße fest
Epigenomics AG
03.06.24 Poseida Therapeutics Announces Virtual 2024 Annual Meeting of Stockholders
Poseida Therapeutics
27.05.24 TME Pharma Announces Convocation of the 2024 Annual General Meeting of Shareholders
TME Pharma AG
15.05.24 Actinium to Host KOL Webinar to Discuss Iomab-ACT Commercial CAR T-Cell Therapy Trial Design, Objectives and Potential Market Opportunity
Actinium Pharmaceuticals
14.05.24 Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in TP53 Positive Patients at the EHA 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Receiving an Iomab-B Led Bone Marrow Transplant in the Phase 3 SIERRA Trial
Actinium Pharmaceuticals
14.05.24 Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024
Poseida Therapeutics
13.05.24 Actinium Announces Multiple Abstracts Highlighting its Antibody Radiation Conjugates Iomab-B and Actimab-A and Novel Linker Technology for Solid Tumors Accepted for Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting
Actinium Pharmaceuticals
13.05.24 Leap Therapeutics Reports First Quarter 2024 Financial Results
Leap Therapeutics
09.05.24 Poseida Highlights Strong Progress on Its Genetic Medicine Programs at the American Society for Gene and Cell Therapy 27th Annual Meeting
Poseida Therapeutics
07.05.24 Actinium Announces KOL Webinar to Highlight Recently Announced Iomab-ACT Trial with Leading FDA Approved Commercial CAR T-Cell Therapy Being Led by the University of Texas Southwestern
Actinium Pharmaceuticals
01.05.24 Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology
Poseida Therapeutics
01.05.24 Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology
Poseida Therapeutics
30.04.24 EQS-News: Epigenomics AG: Executive Board member Jens Ravens leaves the Company on April 30, 2024
Epigenomics AG
30.04.24 EQS-News: Epigenomics AG: Ausscheiden des Vorstands Jens Ravens zum 30. April 2024
Epigenomics AG
25.04.24 TME Pharma Publishes 2023 Financial Results and Provides Operating Update
TME Pharma AG
23.04.24 TME Pharma Announces 33% of Patients Receiving NOX-A12 in Combination With Bevacizumab and Radiotherapy Achieve Two‑Year Survival in GLORIA Phase 1/2 Trial in Brain Cancer
TME Pharma AG
18.04.24 Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting
Actinium Pharmaceuticals
18.04.24 Poseida Therapeutics Announces Strong Lineup of Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting
Poseida Therapeutics
17.04.24 Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline Focus
Poseida Therapeutics
11.04.24 Leap Therapeutics Announces $40 Million Private Placement
Leap Therapeutics
10.04.24 EQS-NVR: Epigenomics AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem Ziel der europaweiten Verbreitung
Epigenomics AG
10.04.24 EQS-NVR: Epigenomics AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Epigenomics AG
08.04.24 Poseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma
Poseida Therapeutics
02.04.24 TME Pharma Receives US FDA Fast Track Designation for Lead Asset NOX-A12 in Brain Cancer
TME Pharma AG
16:40
TME Pharma AG
TME Pharma Announces a Financing Guarantee Agreement and the Launch of Capital Increase of Minimum 2.2 Million Euros
15:35
TME Pharma AG
TME Pharma Announces Publication in Nature Communications of Biomarker Data From NOX-A12 Gloria Phase 1/2 Trial in Glioblastoma
08:00
Actinium Pharmaceuticals
Actinium Presents First Ever Data Demonstrating Actimab-A in Combination with Leading Menin Inhibitors Leads to Anti-Tumor Control and Potent Leukemic Cell Killing in Preclinical Acute Myeloid Leukemia Models at the 2024 EHA Congress
Fr
Actinium Pharmaceuticals
Actinium Highlights Oral Presentation at EHA 2024 Annual Congress Featuring Improved Outcomes in TP53 Positive Patients Receiving Iomab-B in the Phase 3 SIERRA Trial
Di
Actinium Pharmaceuticals
Actinium Announces Results of Actimab-A + CLAG-M Combination Trial Highlighted in Oral Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting
10.06.24
Actinium Pharmaceuticals
Actinium Highlights Mutation Data from the Phase 3 SIERRA Trial of Iomab-B and Novel Linker Technology to Support Solid Tumor Antibody Radiation Conjugate Development at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting
05.06.24
Epigenomics AG
Epigenomics AG: BaFin setzt Geldbuße fest
03.06.24
Poseida Therapeutics
Poseida Therapeutics Announces Virtual 2024 Annual Meeting of Stockholders
27.05.24
TME Pharma AG
TME Pharma Announces Convocation of the 2024 Annual General Meeting of Shareholders
15.05.24
Actinium Pharmaceuticals
Actinium to Host KOL Webinar to Discuss Iomab-ACT Commercial CAR T-Cell Therapy Trial Design, Objectives and Potential Market Opportunity
14.05.24
Actinium Pharmaceuticals
Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in TP53 Positive Patients at the EHA 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Receiving an Iomab-B Led Bone Marrow Transplant in the Phase 3 SIERRA Trial
14.05.24
Poseida Therapeutics
Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024
13.05.24
Actinium Pharmaceuticals
Actinium Announces Multiple Abstracts Highlighting its Antibody Radiation Conjugates Iomab-B and Actimab-A and Novel Linker Technology for Solid Tumors Accepted for Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting
13.05.24
Leap Therapeutics
Leap Therapeutics Reports First Quarter 2024 Financial Results
09.05.24
Poseida Therapeutics
Poseida Highlights Strong Progress on Its Genetic Medicine Programs at the American Society for Gene and Cell Therapy 27th Annual Meeting
07.05.24
Actinium Pharmaceuticals
Actinium Announces KOL Webinar to Highlight Recently Announced Iomab-ACT Trial with Leading FDA Approved Commercial CAR T-Cell Therapy Being Led by the University of Texas Southwestern
01.05.24
Poseida Therapeutics
Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology
01.05.24
Poseida Therapeutics
Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology
30.04.24
Epigenomics AG
EQS-News: Epigenomics AG: Executive Board member Jens Ravens leaves the Company on April 30, 2024
30.04.24
Epigenomics AG
EQS-News: Epigenomics AG: Ausscheiden des Vorstands Jens Ravens zum 30. April 2024
25.04.24
TME Pharma AG
TME Pharma Publishes 2023 Financial Results and Provides Operating Update
23.04.24
TME Pharma AG
TME Pharma Announces 33% of Patients Receiving NOX-A12 in Combination With Bevacizumab and Radiotherapy Achieve Two‑Year Survival in GLORIA Phase 1/2 Trial in Brain Cancer
18.04.24
Actinium Pharmaceuticals
Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting
18.04.24
Poseida Therapeutics
Poseida Therapeutics Announces Strong Lineup of Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting
17.04.24
Poseida Therapeutics
Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline Focus
11.04.24
Leap Therapeutics
Leap Therapeutics Announces $40 Million Private Placement
10.04.24
Epigenomics AG
EQS-NVR: Epigenomics AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem Ziel der europaweiten Verbreitung
10.04.24
Epigenomics AG
EQS-NVR: Epigenomics AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
08.04.24
Poseida Therapeutics
Poseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma
02.04.24
TME Pharma AG
TME Pharma Receives US FDA Fast Track Designation for Lead Asset NOX-A12 in Brain Cancer
Musterdepot - © Ismagilov / Shutterstock

Das kostenlose Musterdepot von ARIVA.DE

Bei einem niedrigen Kurs einsteigen, bei einem hohen Kurs wieder verkaufen – es klingt einfach, an der Börse Erfolg zu haben. Tatsächlich brauchen Aktionäre gute Nerven, wenn die Kurse auf und ab schwanken. Realistische Anlageziele, eine klare Linie bei der Auswahl der Wertpapiere und das clevere Einsetzen bestimmter Ordertypen gehören zum Handwerk beim Handel mit Wertpapieren.

Um ein Gefühl dafür zu bekommen, welche Strategien in welchen Börsenphasen fruchten, können Nutzerinnen und Nutzer bei ARIVA.DE kostenlos ein Musterdepot anlegen und Wertpapiere wie Anleihen, Aktien, Derivate oder Fonds virtuell im Musterdepot handeln. Die Orders werden zum Schein ausgeführt und finden sich dann in einem virtuellen Musterdepot, ohne dass die Papiere tatsächlich ge- oder verkauft werden. So lassen sich Anlagestrategien testen, ohne Geld zu riskieren.

Viele Nutzer bauen auf ARIVA.DE im Musterdepot ihr reales Depot nach, das ein Broker für sie führt. Grund: Beim Musterdepot auf ARIVA.DE ist jede Position mit den zugehörigen News, dem Forum und der Profilseite verlinkt. Über die Aktien auf dem Laufenden zu bleiben, ist durch das Musterdepot sehr einfach. Möglich ist es auf ARIVA.DE auch, interessante Wertpapiere in eine Watchlist aufzunehmen, um ihre Entwicklung im Auge zu behalten. Nutzer können dabei Kursgrenzen vorgeben und sich bei Erreichen benachrichtigen lassen.

Übrigens: Wer ein virtuelles Musterdepot im Rahmen eines der Börsenspiele von ARIVA.DE eröffnet, hat einen weiteren Lerneffekt: Beim Börsenspiel wird ein Budget vorgegeben, und für jede Transaktion fallen virtuelle Gebühren an. Das macht den „Scheinhandel“ noch realistischer.